StockData

Kura Oncology vs Tango Therapeutics

KURA and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KURA and TNGX compare

Tango Therapeutics is the larger company, worth 5.9 times as much as Kura Oncology ($3.8B against $654M).

Tango Therapeutics keeps more of each dollar of sales as profit, with a net margin of −230% compared with −369% at Kura Oncology.

Tango Therapeutics scores higher on the StockData Score (10 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKURATNGX
Size and price
Market cap$654M$3.8B
Share price$7.35$22.71
Change, 1 year−33.7%184%
Change, 5 years−47.5%119%
Beta (5Y)1.271.18
Employees260137
StockData Score
Total score110 (better)
Valuation score00
Growth score02 (better)
Performance score02 (better)
Health score16 (better)
Dividend score00
Valuation
P/S8.2× (better)71.2×
P/B36.4×3.7× (better)
FCF yield−13.6%−3.8% (better)
Fair value–$9.65
Margin of safety–−135%
Growth
Revenue growth (TTM)–121%
Revenue growth, 5Y average–52.1%
Profitability
Operating margin−394%−253% (better)
Net margin−369%−230% (better)
FCF margin−112% (better)−268%
Return on equity−225%−21.3% (better)
Financial health
Debt / equity0.55 (better)0.00
Interest coverage−227.1×–
Current ratio3.6050.82 (better)
Altman Z-score−3.5746.40 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions98.0%127%
Held by insiders2.6%11.7%
Insider net buying, 12 months$1.3M (better)−$8.1M
Short interest, % of float14.6%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.